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ARTICLE
The GM-CSF–IRF5 signaling axis in eosinophils
promotes antitumor immunity through activation of
type I T cell responses
Isabelle C. Arnold1,2, Mariela Artola-Boran1, Alessandra Gurtner1, Katrin Bertram1, Michael Bauer1, Ziva Frangez3, Burkhard Becher2,
Manfred Kopf4, Shida Yousefi3, Hans-Uwe Simon3,5, Alexandar Tzankov6, and Anne Müller1
The depletion of eosinophils represents an efficient strategy to alleviate allergic asthma, but the consequences of prolonged
eosinophil deficiency for human health remain poorly understood. We show here that the ablation of eosinophils severely
compromises antitumor immunity in syngeneic and genetic models of colorectal cancer (CRC), which can be attributed to
defective Th1 and CD8+ T cell responses. The specific loss of GM-CSF signaling or IRF5 expression in the eosinophil
compartment phenocopies the loss of the entire lineage. GM-CSF activates IRF5 in vitro and in vivo and can be administered
recombinantly to improve tumor immunity. IL-10 counterregulates IRF5 activation by GM-CSF. CRC patients whose tumors
are infiltrated by large numbers of eosinophils also exhibit robust CD8 T cell infiltrates and have a better prognosis than
patients with eosinophillow tumors. The combined results demonstrate a critical role of eosinophils in tumor control in CRC and
introduce the GM-CSF–IRF5 axis as a critical driver of the antitumor activities of this versatile cell type.
Introduction
Eosinophils are granulocytes arising in the bone marrow from
granulocyte-monocyte progenitors; they are released into the
peripheral blood as terminally differentiated cells and rapidly
migrate to their target tissues. Eosinophils are classically asso-
ciated with type 2 inflammation that is characteristic of parasite
infections and further are known to contribute critically to the
pathogenesis of allergic asthma (Lee et al., 2004). In asthma,
eosinophils drive multiple hallmarks of the disease, including
mucus production, smooth muscle cell hyperplasia, angiogene-
sis, and fibrosis (Bergeron et al., 2009), and thereby contribute
to asthma exacerbations. Targeting eosinophils is now a well-
established strategy for the treatment of patients with severe
eosinophilic asthma that are refractory to standard of care
(i.e., steroid-based treatments; Castro et al., 2011). In the steady
state, only small numbers of eosinophils are released from the
bone marrow; these numbers increase dramatically during type
2 inflammation (Travers and Rothenberg, 2015). Eosinopoiesis
during inflammation and in the steady state is dependent on the
cytokine IL-5 (Kopf et al., 1996). IL-5 signaling requires the
common β-chain, which is shared with the cytokines IL-3 and
GM-CSF. IL-5 acts on eosinophils at multiple time points during
their lifespan. In addition to stimulating the differentiation and
maturation of eosinophil-committed progenitors in the bone
marrow, contributing to eosinophil egress from the bone mar-
row, IL-5 synergizes with chemotactic factors such as eotaxin-
1 (CCL11) to attract eosinophils to tissues, primes eosinophils for
activation in response to various mediators, and extends the
eosinophil lifespan by blocking apoptosis (Jung and Rothenberg,
2014; Travers and Rothenberg, 2015). IL-5 overexpression is
sufficient to induce massive eosinophilia but alone does not
induce tissue damage (Dent et al., 1990). IL-5 neutralization or
overexpression thus represents a convenient tool to study the
contribution of eosinophils to health and disease.
Eosinophils constitute an abundant cellular infiltrate of solid
tumors (Lotfi et al., 2007). Interestingly, in historical surveys,
tumor-associated tissue eosinophilia tends to be associated with
improved prognosis in solid cancers, in particular in malignan-
cies of the gastrointestinal tract such as gastric cancer (Cuschieri
et al., 2002; Iwasaki et al., 1986) and colorectal cancer (CRC;
Fernández-Aceñero et al., 2000; Nielsen et al., 1999). However,
only very few experimental studies have mechanistically ad-
dressed eosinophil functions in models of carcinogenesis. In a
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recent study, eosinophils have been reported to enhance anti-
tumor immune responses by normalizing the tumor vasculature,
promoting macrophage polarization toward an inflammatory
phenotype and enhancing the infiltration of CD8+ T cells through
the release of CCL5, CXCL9, and CXCL10 (Carretero et al., 2015).
Eosinophils were also shown to restrict melanoma growth upon
IL-33 treatment through the recruitment and activation of cy-
totoxic T cells and natural killer (NK) cells (Lucarini et al., 2017).
In addition, eosinophils have been suggested to exert direct tu-
moricidal properties by releasing their granular content. To
examine possible beneficial or detrimental functions of eosino-
phils in syngeneic and genetic CRCmodels, we took advantage of
various constitutive and inducible models of eosinophil defi-
ciency or overproduction. We found that CRC cells grow more
rapidly and form larger tumors inmice that lack eosinophils; this
critical role of eosinophils could be linked to their ability to drive
CD4+ and CD8+ T cell responses within the tumor microenvi-
ronment (TME). The antitumor activities of eosinophils were
found to be activated by GM-CSF signaling through the tran-
scription factor IRF-5 and to be counterregulated by IL-10. The
administration of recombinant GM-CSF effectively stimulates
antitumor immunity in an eosinophil-dependent manner. The
prognostic value of eosinophil infiltration and link between the
presence of eosinophils and intratumoral T cell responses could
further be confirmed in a large cohort of CRC patients, impli-
cating this cell type in tumor immunity and making it an at-
tractive target in immunotherapy against cancer.
Results
Eosinophils infiltrate subcutaneously growing MC38 tumors,
and eosinophil frequencies are inversely associated with
tumor growth
Eosinophils are known to infiltrate various solid tumors, in-
cluding CRC. To examine their recruitment to and activation in
the TME, we profiled the immune cell infiltrate of the subcu-
taneously growing CRC cell line MC38 at days 7, 10, and 15 after
inoculation into the flanks of C57/BL6 mice. Eosinophils were
identified as CD45+CD11b+MHCII−Ly6G− and Siglec F+ cells (see
gating strategy in Fig. S1 A) and were clearly distinguishable
from all other leukocyte populations in the TME. The recruit-
ment of eosinophils was an early event in the course of MC38
growth, with eosinophils constituting one of several dominant
leukocyte populations at day 7 after inoculation alongside
monocytes, NK cells, and T cells, as assessed with respect to both
their frequencies (Fig. 1, A and B) and absolute numbers (Fig. S1
B). At the later time points, eosinophil frequencies dwindled as
tumors began to grow out and macrophages became more
dominant (Fig. 1, A and B; and Fig. S1 B). The identity of eosi-
nophils was confirmed by the specific loss of this, but not other,
leukocyte populations in the TME of PHIL mice (Fig. 1 A), which
transgenically express diphtheria toxin under the eosinophil
peroxidase (EPO) promoter and are known to be entirely devoid
of eosinophils in all tissues of the body (Lee et al., 2004). Eosi-
nophils in the TME were more activated than their counterparts
in the circulation, as judged by their expression of CD11b and
Siglec F (Arnold et al., 2018; Griseri et al., 2015), but exhibited
reduced granularity and concomitant reduced expression of the
degranulation marker CD63 and the chemokine receptor CCR3
(Fig. 1 C). To addresswhether eosinophils contribute functionally
to antitumor immune responses and tumor control, we com-
pared the subcutaneous growth of MC38 cells in WT and
eosinophil-deficient PHIL mice. Eosinophil deficiency led to
larger and heavier tumors over time and at the study endpoint
(Fig. 1, D–F; and Fig. S1, C and D). The depletion of eosinophils by
another strategy (i.e., administration of a neutralizing antibody
against IL-5) was effective at reducing eosinophil infiltration
in the TME (Fig. S1, C and D) and had similar effects on MC38
tumor size and weight at the study endpoint as genetic eosino-
phil deficiency (Fig. 1 G). In both settings of eosinophil defi-
ciency, we observed an increase in tumor-infiltrating
macrophages, but not monocytes (not shown). Larger and
heavier tumors were further also observed upon eosinophil
depletion in a second murine CRC model (i.e., CT26 colon car-
cinoma cells transplanted onto the flanks of BALB/c mice;
Fig. 1 H). To examine whether an excess of eosinophils would
have the opposite effect on tumor growth than eosinophil de-
ficiency, we inoculated mice that transgenically and constitu-
tively overexpress IL-5 in T cells under the control of the CD2
promoter (Dent et al., 1990) with MC38 cells. These mice de-
veloped extreme eosinophilia, which was evident not only in
the bone marrow, blood, and spleen, as reported previously
(Dent et al., 1990; data not shown), but also in the TME (Fig. S1,
C and D); eosinophils in the tumors of IL-5–transgenic mice
were at least as mature and activated, as judged by their Siglec F
and CD11b expression, as eosinophils in WT mice (Fig. S1 E).
Interestingly, MC38 tumors of IL-5–transgenic mice were sig-
nificantly smaller and weighed less at the study endpoint than
those of WT littermates (Fig. 1 I). The combined data indicate
that the frequency of tumor-infiltrating eosinophils is inversely
associated with tumor growth in this model.
Eosinophils are required for T cell activation in the TME
To address the mechanistic basis of the role that eosinophils play
in tumor control, we examined antitumor immune responses in
the TME of MC38 tumors growing on WT, eosinophil-deficient
PHIL and IL-5–transgenic mice. Both CD4+ and CD8+ T cells are
known to be critically involved in tumor control in this model,
which we verified for CD8+ T cells by applying several doses of a
CD8+ T cell–depleting antibody (Fig. S2 A). Intratumoral CD4+
and CD8+ T cell frequencies and absolute numbers were similar
in PHIL mice, IL-5–depleted mice, and their WT littermates and
also in IL-5–transgenic mice and their littermates (Fig. S2 B).
However, we observed strong and consistent differences in IFN-γ
and TNF-α production by both CD4+ and CD8+ T cells upon re-
stimulation with PMA and ionomycin, with reduced cytokine
production in the absence of eosinophils (Fig. 2, A and B; and Fig.
S2 C) and increased cytokine production in their excessive
presence (Fig. 2, C and D). The effects on cytokine production
were also seen in CD8+ T cells that were restimulated with a
tumor-specific peptide (Fig. 2, E and F; and Fig. S2 C) and were
mirrored by corresponding changes in granzyme B expression
and expression of the activation marker CD69 by CD8+ T cells
(Fig. 2, G and H). The effects of eosinophil loss or overproduction
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on T cell activation were specific to the TME and were not re-
capitulated in the draining inguinal LNs of tumor-bearing mice
(Fig. S2, D and E; data not shown). Quite to the contrary, whereas
in WT mice, ectopic tumor growth led to emigration of T cells
from the LNs (presumably to the tumor), this was not the case
for PHIL or IL-5–depleted mice (Fig. S2, D and E); rather, we
found evidence of retention of activated T cells in the tumor-
draining LNs under conditions of eosinophil deficiency, indi-
cating that T cells fail to exit the LN and migrate to their target
tissues if eosinophils are absent (Fig. S2, D and E). The effects of
eosinophil deficiency on T cell activation or the local expansion
of activated T cells specifically affected the CD62LloCD44+ ef-
fector memory pool of CD4+ T cells (Fig. 2 I) and were not ob-
served for naive CD62LhiCD44− T cells and CD62LhiCD44+ central
memory T cells, the frequencies of which were normal (data not
shown). The combined results suggest a critical role of eosino-
phils during the local activation or expansion of effector T cells
rather than during their priming in LNs. Consistent with this
model, T cells were found clustered and in close proximity to
eosinophils in WT mice, whereas they appeared to be more
dispersed in PHIL mice (Fig. 2 J). The combined results indicate
that eosinophils promote the recruitment of cytokine-producing
CD4+ and CD8+ T cells to the TME.
Eosinophil depletion impairs T helper type 1 (Th1) responses
and enhances the tumor burden in the ApcMin/+ model of
intestinal tumorigenesis
To confirm our findings in a genetic model of intestinal tu-
morigenesis, we depleted eosinophils for three consecutive
weeks in ApcMin/+ mice (Min, multiple intestinal neoplasia)
through regular twice-weekly injection of anti–IL-5 antibody
beginning at 12 wk of age. ApcMin/+ mice carry a heterozygous
germline mutation at codon 850 of the Apc gene (Su et al., 1992),
and loss of the second (WT) Apc allele in intestinal epithelium
precedes adenoma formation (Luongo et al., 1994). ApcMin/+ mice
are known to develop adenomas along the length of the small
intestine and colon (Su et al., 1992). Eosinophil depletion by
anti–IL-5 treatment was highly efficient also in this strain, as
determined in colonic tumor tissue and adjacent normal colonic
lamina propria (Fig. 3 A). Eosinophils were enriched in the TME
Figure 1. Eosinophils are recruited to the
TME and promote tumor control in an ectopic
model of colon cancer. (A–C) PHIL mice and
their WT littermates were subcutaneously in-
jected in both flanks with 5 × 105 MC38 colon
cancer cells. Tumors were analyzed at 7, 10, and
15 d after injection (n = 14–18 tumors per gen-
otype) with respect to intratumoral eosinophil
frequencies (in percentage of all CD45+ leuko-
cytes; A), the composition of the overall leuko-
cyte compartment (WT only; B), and the
expression of the indicated surface markers
(along with granularity, in corresponding blood,
n = 9 versus tumor, n = 18) in the eosinophil
compartment of WT mice (C). (D–F) PHIL mice
and their WT littermates were injected with
MC38 cells and analyzed over time (D) and at the
study endpoint (day 15; E) with respect to tumor
weights and volumes. Macroscopic images of
representative tumors are shown in F; scale bar
represents 0.5 cm (n = 14–15 tumors per geno-
type). (G) C57BL/6 mice were injected with
MC38 cells and treated twice weekly with 250
µg/dose of isotype control (iso) or anti–IL-5 an-
tibody. Tumor weights and volumes at the end-
point are shown (n = 9–13 tumors per condition).
(H) BALB/c mice were injected with 5 × 105 CT26
colon cancer cells and received twice-weekly
injections of 250 µg/dose of isotype control
(iso) or anti–IL-5 antibody. Tumor weights and
volumes at the study endpoint (day 20) are
plotted (n = 28–32 tumors per condition). (I) IL-
5–transgenic mice and their WT littermates were
injected with MC38 cells and analyzed with re-
spect to tumor weights and volumes at the study
endpoint (n = 12 tumors per genotype). Data from
at least two and up to three independent ex-
periments are pooled throughout. Symbols rep-
resent individual tumors; horizontal lines indicate
medians. *, P < 0.05; **, P < 0.01; and ***, P <
0.001; as calculated by Mann–Whitney test.
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of eosinophil-replete ApcMin/+ mice treated with isotype control
antibody relative to adjacent normal colon tissue (Fig. 3 A) and
expressed higher levels of the activation marker CD11b, but not
Siglec F (Fig. 3 B). Eosinophil depletion resulted in a higher
adenoma burden in the colon (Fig. 3 C) and small intestine (Fig.
S2 F) of ApcMin/+ mice. Adenomas in ApcMin/+ mice developed
predominantly in the ileum and distal colon (Fig. 3 D), which
was true irrespective of the eosinophil status and confirmed
previous studies in ApcMin/+ mice (Su et al., 1992). Interestingly,
colonic adenomas harvested from control antibody–treated mice
exhibited a higher abundance of CD4+ T cells (Fig. 3 E), higher
frequencies of CD4+ T cells expressing IFN-γ and GM-CSF than
adjacent normal colonic tissue, and higher frequencies than
tumors from eosinophil-depleted mice (Fig. 3, F and G). More
CD4+ T cells were actively cycling (i.e., stained positive for Ki67)
in eosinophil-replete tumors relative to adjacent tissue or
eosinophil-depleted tumors (Fig. S2 G). In contrast, CD8+ T cell
numbers and the frequencies of IFN-γ–expressing CD8+ T cells
did not differ as a consequence of eosinophil ablation (Fig. S2, H
and I). Interestingly, the absolute numbers of intratumoral CD4+
T cells expressing IFN-γ and GM-CSF per gram of tissue not only
showed the same trend but also were inversely correlated with
adenoma multiplicity across mice in the study (Fig. 3 H). The
combined results suggest that eosinophils contribute to tumor
control in this genetic tumor model through the recruitment
and/or activation of tumor-infiltrating CD4+ T cells.
Eosinophils in the TME are negatively regulated by IL-10
The regulatory cytokine IL-10 is known to dampen antitumor
immune responses in the TME, with effects described on a va-
riety of tumor-infiltrating cells of lymphoid and myeloid origins.
We speculated that eosinophil activities in the TME might
be regulated by IL-10. We first assessed which cell types produce
IL-10 in MC38 tumors using a dual Il10/Foxp3 reporter in
which the expression of Thy1.1 from a BAC transgene is driven
by Il10 regulatory elements and GFP is expressed under the
control of the Foxp3 promoter (Maynard et al., 2007). Of all IL-
10–expressing cells in the TME, the vast majority were CD45+
leukocytes of myeloid origin (∼80% of Thy1.1+ cells), with most
Thy1.1+ cells expressing the monocyte and macrophage markers
Ly6C and F4/80, respectively, in addition to CD11b (Fig. 4 A).
One half to two thirds of intratumoral monocytes and macro-
phages were positive for IL-10/Thy1.1 (Fig. 4 A); such frequen-
cies were comparable to (macrophages) or slightly higher
(monocytes) than IL-10/Thy1.1+ frequencies of their cellular
counterparts in the colonic lamina propria of the samemice (Fig.
S3 A). One of the few nonmyeloid cellular sources of intra-
tumoral IL-10 were Foxp3+ regulatory T cells (Fig. 4 A and Fig. S3
B), which however contributed little (2%) to the overall IL-10+
leukocyte pool. In addition to the various leukocyte sources of
IL-10, MC38 cells also express copious amounts of this cytokine
(Fig. S3 B). To address whether IL-10 in the TME affects eosin-
ophil activities, we crossed Il10rafl/fl mice with a strain that
Figure 2. Eosinophils drive tumor-specific
T cell responses in the TME. (A–H) PHIL (A,
B, E, G, and H) and IL-5-transgenic mice (C, D,
and F) and their littermates (WT) were subcu-
taneously injected with 5 × 105 MC38 cells and
analyzed after 15 d with respect to the fre-
quencies of intratumoral IFN-γ+ and TNF-α+
CD4+ T cells and of IFN-γ+ and TNF-α+ CD8+
T cells as assessed by intracellular cytokine
staining upon restimulation with PMA/ionomycin
and of IFN-γ+ CD8+ T cells upon stimulation with
MC38-specific peptide where indicated (“pep-
tide”; A–F). Littermates were used throughout
(n = 7–12 tumors per genotype); note that the IL-
5–transgenic line generally mounts weaker in-
tratumoral T cell responses than the PHIL line,
which is reflected in the generally lower fre-
quencies in C, D, and F relative to A, B, and E.
Tumors were further stained for expression of
the activation marker CD69 and granzyme B in
the CD8 compartment (G and H, n = 6–7 tumors
per genotype). (I) CD4+ effector memory cells
were identified by staining for CD62L and CD44,
of the mice shown in A–F as well as tumor-
bearing WT mice treated with anti–IL-5 neutral-
izing antibody (n = 5–16 tumors per condition). (J)
Representative micrographs of eosinophil per-
oxidase (EPX)– and CD3-stained formalin-fixed
sections of MC38 tumors growing on WT and
PHILmice. Scale bars represent 10 µm. Data from
one representative of at least two independent
experiments are shown throughout. *, P < 0.05;
**, P < 0.01; as calculated by Mann–Whitney test
(A–H) or by one-way ANOVA with Tukey’s post-
test (I).
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expresses Cre under the eosinophil peroxidase promoter (Eo-
Cre; Doyle et al., 2013) to generate mice in which only the eo-
sinophil compartment lacks the IL-10 receptor (IL-10R), and
transplanted them subcutaneously with MC38 cells. Eo-Cre ×
Il10rafl/fl mice exhibited a phenotype that was in stark contrast to
the phenotypes of eosinophil-deficient mice, as they showed
improved control of the tumor burden (Fig. 4 C), with an effect
size that was similar to the global neutralization of the IL-10R
with a neutralizing antibody (Fig. S3 C). Eo-Cre × Il10rafl/fl mice
showed strongly enhanced numbers of tumor-infiltrating eosi-
nophils (Fig. 4 D), and intratumoral IL-10R–deficient eosinophils
expressed copious amounts of the chemokine CCL5 (Fig. S3 D).
CCL5 is required for eosinophil recruitment into target tissues;
therefore, its excessive production provides an explanation for
the overrepresentation of eosinophils in tumors of Eo-Cre ×
Il10rafl/fl mice. The improved tumor control observed in this
Figure 3. Eosinophils are recruited to adenomas of ApcMin/+ mice and promote antitumor CD4+ T cell responses. ApcMin/+ mice were treated twice
weekly with 250 µg of anti–IL-5 or isotype control antibody for 3 wk beginning at 12 wk of age (n = 14–17 mice per condition). At the study endpoint, adenoma
formation in the colon was quantified by counting individual polyps with diameters of >1 mm; colonic adenomas were harvested along with adjacent normal
(tumor-free) colonic tissue per mouse for flow cytometric analysis of the TME relative to normal colonic lamina propria. (A) Eosinophil numbers per milligram
of tumor and adjacent normal tissue of mice treated with anti–IL-5 or isotype control antibody. (B) Eosinophil activation in tumor and normal tissue of isotype
control antibody–treated mice, as assessed by flow cytometric analysis of CD11b and Siglec F (SigF) expression. (C) Colonic adenoma counts of anti–IL-5 or
isotype control antibody–treated mice. (D) Representative macroscopic images of the colon of an ApcMin/+ mouse treated with anti–IL-5 or isotype control
antibody. (E) CD4+ T cell numbers per milligram of colonic adenoma and adjacent normal tissue of mice treated with anti–IL-5 or isotype control antibody.
(F and G) Intratumoral frequencies of IFN-γ+ and GM-CSF+ CD4+ T cells in tumor and normal colon tissue of the mice shown in A–C. Summary plots are shown
in F alongside representative FACS plots in G. Numbers indicate frequencies (%) in respective gates. (H) Intratumoral counts per mg of tissue, of IFN-γ+ CD4+
T cells (ρ, correlation coefficient = −0.7368) and GM-CSF+ CD4+ T cells (ρ = −0.6507) relative to tumor counts. Data in A, B, E, and H are pooled from two (n =
8–11 samples per condition), in C and F from three independent experiments (n = 10–24 samples per experiment). Horizontal lines indicate medians. *, P <
0.05; **, P < 0.01; and ***, P < 0.001; as calculated by Mann–Whitney test (B and C), by one-way ANOVA with Tukey’s post-test (A, E, and F) or by linear
regression (H).
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model correlated with higher frequencies of IFN-γ– and TNF-
α–expressing CD4+ and CD8+ T cells (Fig. 4, E–G) andwith higher
frequencies of intratumoral TNF-α+ monocytes and macro-
phages (Fig. 4 H). Indeed, the entire intratumoral production of
TNF-α increased in the tumors of Eo-Cre × Il10rafl/fl mice, which
could be traced to CD45+ leukocytes (Fig. 4 I). Interestingly, the
eosinophil-specific loss of STAT3, a critical transcription factor
mediating IL-10 signaling, in Eo-Cre × Stat3fl/fl mice phenocopied
the effects of IL-10R loss in eosinophils (Fig. S3, E–G). In con-
trast, the eosinophil-specific ablation of TGF-β signaling by
crossing of Tgfbr2fl/fl with Eo-Cre mice had no effect on the tu-
mor burden (Fig. S3 H). The combined results indicate that eo-
sinophils have antitumor activities that are negatively regulated
by the IL-10–IL-10R–STAT3 signaling axis, but not by TGF-β; one
potentially relevant feature of the TME of tumors growing in the
absence of IL-10 signaling in eosinophils is the increased pro-
duction of TNF-α.
Due to their much more efficient tumor control, Eo-Cre ×
Il10rafl/fl mice represent a model in which the contribution of
eosinophils to tumor control can be studied mechanistically. We
first examined the possibility that tumor-infiltrating eosinophils
themselves have tumoricidal properties. To this end, we co-
cultured eosinophils derived from bone marrow by differenti-
ation with FLT3 ligand (FLT3L), stem cell factor, and IL-5 with
MC38 cells in vitro at 1:2 ratios, with and without the addition of
proinflammatory cytokines that are abundant in the TME. Eo-
sinophils showed no cytotoxic activity toward MC38 cells under
these conditions; in contrast, exposure to TNF-α, but not to GM-
CSF, IFN-γ, or TSLP (Thymic stromal lymphopoietin), killed a
small but robust fraction of tumor cells (Fig. S3 I). The cytotoxic
effect of TNF-α was dose dependent and required TNF-α re-
ceptor I (TNFRI) expression on MC38 cells, as MC38 cells in
which we had deleted the TNFRI gene by genomic editing were
resistant to TNF-α–induced apoptosis (Fig. S3, J–L). To examine
whether TNF-α contributes to antitumor immunity in Eo-Cre ×
Il10rafl/fl mice, we depleted TNF-α using a neutralizing antibody
for the duration of the experiment. TNF-α–depleted tumors
were larger and heavier than those depleted with a control an-
tibody; this effect was specific to Eo-Cre × Il10rafl/fl mice (Fig.
S3 M). To address whether TNF-α acts by killing tumor cells
in vivo, we compared the growth of TNFRI-positive and -negative
cells in Eo-Cre × Il10rafl/fl mice and observed a trend toward larger
Figure 4. Eosinophil activities in the TME are
suppressed by IL-10. (A and B) IL-10 reporter
(10BiT) mice were subcutaneously injected with
5 × 105 MC38 cells and analyzed after 15 d with
respect to their intratumoral frequencies of
Thy1.1 (IL-10)+ myeloid cells, granulocytes, and
T cells. Average frequencies as assessed in in-
dependent tumors are shown in A alongside
representative FACS plots for the indicated ma-
jor IL-10–producing myeloid populations in B (n =
8 tumors). (C–I) Eo-Cre × Il10rafl/fl mice and their
Cre-negative littermates were subcutaneously
injected with 5 × 105 MC38 cells and analyzed
after 15 d with respect to their tumor weights and
volumes (C), their intratumoral frequencies of
eosinophils (D), and their intratumoral frequencies
of IFN-γ+ and TNF-α+ CD4+ and CD8+ T cells (F,
representative FACS plots in E; PMA and ion-
omycin) and IFN-γ+ CD8+ T cells upon restim-
ulation with MC38-specific peptide (G). (H)
Frequencies of TNF-α+ monocytes and macro-
phages among their respective parent populations,
shown alongside representative FACS plots for
macrophages. (I) Frequencies of TNF-α+ cells
among CD45+ leukocytes and among all CD45−
cells in the tumor. Data in C–I are pooled from
three independent studies, n = 17–20 tumors per
genotype. *, P < 0.05; **, P < 0.01; and ***, P <
0.001; as calculated by Mann–Whitney test.
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and heavier tumors produced by TNFRI-negative cells at day 10
after tumor cell injection and at the study endpoint (Fig. S3 N).
The combined results indicate that (1) eosinophils exhibit no
obvious cytotoxic activity toward MC38 tumor cells in vitro, (2)
TNF-α is a critical cytokine in MC38 immune control with di-
rect cytotoxic activity on tumor cells, and (3) IL-10–STAT3
signaling in eosinophils controls the intratumoral availability
of TNF-α.
GM-CSF signaling is required and can be exploited for reducing
MC38 tumor growth
Eosinophils require the aforementioned cytokine IL-5, as well as
GM-CSF, for their production in the bone marrow from myeloid
progenitors, as well as their terminal differentiation and sur-
vival (Davoine and Lacy, 2014; Yamaguchi et al., 1988a, 1988b).
Both cytokines bind to a distinct receptor α-chain (IL-5R-α,
CSF2R-α), that upon ligand binding dimerizes with, and signals
via, the shared β-chain. We generated a conditional eosinophil-
specific knockout of the β-chain by crossing Csf2rbfl/fl mice with
the above-mentioned Eo-Cre strain. Csf2rb deletion in the eo-
sinophil lineage had no effect on eosinophil frequencies in the
bone marrow, blood, or spleen (Fig. S4 A) and only modestly
reduced the frequencies of intratumoral eosinophils (Fig. S4 B).
This observation is consistent with the Eo-Cre promoter being
active only in eosinophils that have egressed from the bone
marrow (Arnold et al., 2018). Interestingly, MC38 cells formed
larger and heavier tumors on Eo-Cre × Csf2rbfl/fl mice than on
their Cre-negative littermates, as determined at the study end-
point (Fig. 5 A). Loss of GM-CSF–IL-5 signaling thus phe-
nocopied the effect of IL-5 neutralization (Fig. 1). The larger
tumors of Eo-Cre × Csf2rbfl/fl mice were infiltrated by similar
absolute numbers per milligram of tissue of CD4+ and CD8+
T cells compared to their WT counterparts (data not shown) but
exhibited lower frequencies of IFN-γ+ and TNF-α+ CD4+ and
CD8+ T cells, as assessed by ex vivo restimulation (Fig. 5, B–D).
This phenotype was mirrored by lower frequencies of CD4+ ef-
fector memory T cells (Fig. 5 E). To address whether the ad-
ministration of IL-5 and/or GM-CSF in recombinant form is
sufficient to promote tumor control, we i.p. administered either
one or both cytokines to tumor-bearing mice once tumors were
palpable. Interestingly, both cytokines effectively reduced the
tumor growth and size at the study endpoint, and the combi-
nation treatment was not more efficient than either cytokine
alone (Fig. 5 F). Both GM-CSF and IL-5 significantly increased
eosinophil recruitment to the TME (Fig. 5 G). The tumor-
suppressive effects of recombinant GM-CSF were dependent
on CSF2R-β signaling in the eosinophil compartment as judged
by parallel treatment of Eo-Cre × Csf2rbfl/fl mice and their WT
littermates (Fig. 5 H). To obtain further proof that GM-CSF, and
not IL-5, activates this signaling pathway in eosinophils, we
compared tumor growth on mice that are deficient for Csf2ra.
Csf2ra−/− animals phenocopied the defect of Eo-Cre × Csf2rbfl/fl
mice with respect to tumor growth (Fig. 5, I and J) as well as
intratumoral T cell responses (Fig. 5, K–M). While a decreased
frequency of neutrophils was observed in the tumors of Csf2ra−/−
mice, other myeloid populations such as macrophages were
unchanged (Fig. S4 C).
Finally, we examined possible beneficial effects of GM-CSF in
two additional tumor models: the CT26 subcutaneous model and
the ApcMin/+ model. In ApcMin/+ mice, regular thrice-weekly GM-
CSF administration during the final month of a cohort main-
tained for 4 mo reduced the colonic adenoma burden (Fig. S4 D);
in the CT26 model, GM-CSF treatment that was initiated once
tumors were palpable reduced the tumor weight and volume
(Fig. S4 E). Interestingly, GM-CSF alone was as effective as
checkpoint blockade with PD-L1– or CTLA4-blocking antibodies
in reducing the tumor burden in both the MC38 and the CT26
tumor models (Fig. S4, E and F). Importantly, no synergy was
observed between checkpoint blockade and GM-CSF treatment
in either model, suggesting that eosinophils act through T cells
to boost antitumor immunity. The combined results indicate
that eosinophil-intrinsic GM-CSF signaling activates the tumor-
suppressive functions of these granulocytes.
GM-CSF activates a transcriptional program in cultured
eosinophils that can be recapitulated in tumor-infiltrating
eosinophils
As GM-CSF has strong effects on tumor growth that are at least
in part driven by its activity on eosinophils, we conducted a gene
expression analysis through RNA sequencing of cultured bone
marrow–derived WT or Csf2ra−/− eosinophils that were exposed
or not to recombinant GM-CSF. Hierarchical clustering revealed
a clear GM-CSF–specific response in WT, but not Csf2ra−/−, eo-
sinophils (Fig. 6 A); gene ontology analysis identified the cate-
gories “inflammatory response,” “cytokine and chemokine
activity,” and “CCR chemokine receptor binding” as being en-
riched for differentially expressed genes upon GM-CSF treat-
ment. A volcano plot of expression changes in WT eosinophils
upon GM-CSF exposure revealed the chemokines CCL4, CCL17,
CCL22, CCL24, and CCL2 and to a lesser extent the cytokines IL-
1α, IL-1β, IL-13, and TNF-α to be among the most obviously GM-
CSF–induced, highly expressed transcripts in eosinophils (Fig. 6,
B and C); none of these transcripts were induced in Csf2ra−/−
eosinophils (data not shown). Several additional immune-related
genes, some of them (Irf5) known to be GM-CSF target genes,
were also identified as being up-regulated by GM-CSF in eosi-
nophils (Fig. S4 G). A shared feature of most identified chemo-
and cytokines is their activity in recruiting or activating T cells
in the TME or other T cell–driven settings. Specifically, the
processes of CD8+ T cell recruitment to sites of immune activa-
tion (CCL4; Castellino et al., 2006), activated (CCL17 and CCL22)
or resting (CCL24) CD4+ T cell recruitment (Patel et al., 1997), and
cytokine expression by activated CD4+ T cells (CCL22; Ushio
et al., 2018) are all known to be driven by one or more of the
differentially expressed eosinophil-derived chemokines. There-
fore, we examined their expression in eosinophils sorted from
adenomas derived from in ApcMin/+ mice relative to eosinophils
sorted from adjacent tissue. We found CCL4 and CCL17, but not
the other three examined CC-motif chemokines, to be up-
regulated in tumor-resident eosinophils, but not control eosi-
nophils from adjacent tissue (Fig. 6 D). The induction of CCL4
and CCL17 correlated well with the higher expression of GM-CSF
in adenomas relative to adjacent tissue (Fig. S4 H). We further
examined the expression of the same chemokines in eosinophils
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sorted from MC38 tumors relative to splenic eosinophils. In
these cells, we found CCL4 and CCL2, and to some extent CCL22,
to be up-regulated in the tumor context (Fig. 6 E). MC38 cells
express GM-CSF, as judged by intracellular staining (Fig. S4 I),
making it seem plausible that tumor-derived GM-CSF drives the
eosinophil response in the TME. The combined results indicate
that eosinophils respond strongly to GM-CSF, which in turn
triggers T cell chemotaxis to and activation in the TME.
GM-CSF drives IRF5 activation in eosinophils
The interferon regulatory factor IRF5 regulates proin-
flammatory gene expression in myeloid cells, is involved in the
polarization and function of M1 macrophages (Saliba et al., 2014;
Weiss et al., 2013), and was identified as a target gene of GM-CSF
signaling in cultured bone marrow–derived eosinophils in the
RNA-sequencing approach described above. We speculated that
eosinophils in the TME might require IRF5 for their antitumor
functions. We first assessed in vitro using splenocyte prepara-
tions from IL-5–transgenic mice whether GM-CSF and/or IL-10
affect IRF5 expression or its activation by phosphorylation of
Ser462. Exposure to GM-CSF induced IRF5 phosphorylation, as
assessed by flow cytometry andWestern blotting, which could be
reversed by IL-10 (Fig. 7, A and B; and Fig. S4 J, left panel). The
validity of the pIRF5 signal in eosinophils could be confirmed in
macrophages (Fig. S4 J, right panel), which are well known to
respond to GM-CSF or LPS exposure (Krausgruber et al., 2011).
IRF5 phosphorylation was associated with enhanced IRF5 ex-
pression (Fig. S4 K), an observation that is consistent with its
autoregulation and that could further be confirmed at the tran-
script level by quantitative RT-PCR of FACS-sorted eosinophils
(Fig. S4 L). GM-CSF–induced eosinophil activation, as judged by
their Siglec F, CD11b, and β-integrin expression, which also was
to some extent counteracted by IL-10 (Fig. 7 C; data not shown).
Interestingly, tumor-infiltrating eosinophils in MC38 tumors,
which cannot sense IL-10 (in Eo-Cre × Il10rafl/fl mice), show
higher levels of IRF5 phosphorylation than eosinophils infil-
trating the tumors of WT littermates (Fig. 7 D), indicating that
IL-10 inhibits IRF5 activation also in vivo. Strong IRF5 phos-
phorylation could further be detected in eosinophils infiltrating
MC38 tumors that had been exposed to recombinant GM-CSF,
and this signal was dependent on GM-CSF receptor expression
on eosinophils (Fig. 7 E). To address whether IRF5 is required for
Figure 5. GM-CSF promotes tumor control
through its activities on eosinophils. (A–E) Eo-
Cre × Csf2rbfl/fl mice and their Cre-negative litter-
mates were subcutaneously injected with 5 × 105
MC38 cells and analyzed after 15 d with respect to
their tumor weights and volumes (A) as well as
their intratumoral frequencies of IFN-γ+ and TNF-
α+ CD4+ T cells (B), IFN-γ+ and TNF-α+ CD8+
T cells (C; PMA/ionomycin), and IFN-γ+ CD8+
T cells upon stimulation with MC38-specific pep-
tide (D; n = 13–14 tumors per genotype). Fre-
quencies of effector memory cells are shown as
well (E). Data in A–E are pooled from two inde-
pendent studies. (F–H) WT C57BL/6 mice (F and
G, n = 15–22 tumors per group) and Eo-Cre ×
Csf2rbfl/fl mice and their Cre-negative littermates
(H, n = 6–14 tumors per group) were injected with
MC38 cells and treated three times weekly with
recombinant GM-CSF or IL-5 as indicated. The
tumor weights and volumes at the study endpoint
are plotted for two (IL-5) and three (GM-CSF) in-
dependently conducted, pooled studies in F and G
and a representative study of two in H. (I–M)
Csf2ra−/−mice andWT controls were injected with
MC38 cells and analyzed after 15 d with respect to
their tumor weights and volumes (I and J) and
their intratumoral frequencies of IFN-γ+ and TNF-
α+ CD4+ T cells and of IFN-γ+ and TNF-α+ CD8+
T cells (K and L; PMA/ionomycin, n = 13–17), and
of IFN-γ+ CD8+ T cells upon stimulation with
MC38-specific peptide (M; n = 4–10). Data in I–L
are pooled from three independent studies; data
in M are from one representative study of three. *,
P < 0.05; **, P < 0.01; and ***, P < 0.001; n.s., not
significant; as calculated by Mann–Whitney test.
Arnold et al. Journal of Experimental Medicine 8 of 17
Eosinophils promote antitumor immunity https://doi.org/10.1084/jem.20190706
D
ow
nloaded from
 http://rupress.org/jem
/article-pdf/217/12/e20190706/1050166/jem
_20190706.pdf by U
niversitat Bern user on 28 Septem
ber 2020
the antitumor activities of eosinophils, we crossed Eo-Cre mice
with Irf5fl/fl mice to generate a composite strain that lacks
IRF5 expression exclusively in the eosinophil compartment.
Interestingly, this strain was unable to control MC38 tumor
growth (Fig. 7 F) and thus phenocopied the defects of GM-CSF
signaling–deficient (Csf2ra−/− and Eo-Cre × Csf2rbfl/fl) mice.
Eosinophils infiltrating the tumors of Eo-Cre × Irf5fl/fl mice
showed lower Siglec F expression, indicating that eosinophil
activation, at least as measured using this parameter, requires
a functional GM-CSF–IRF5 signaling axis (Fig. S4 M). More-
over, regular doses of recombinant GM-CSF promoted tumor
control in WT mice, but not their Eo-Cre × Irf5fl/fl littermates
(Fig. S4 N). Finally, we found that the mean fluorescence in-
tensity (MFI) of IRF5 phosphorylation in eosinophils, and
their activation as assessed by CD11b and Siglec F expression,
as well as the GM-CSF production by adenomas in ApcMin/+
mice were inversely correlated with adenoma multiplicity
(Fig. 7 G). The combined results suggest that a newly
Figure 6. Eosinophils respond to GM-CSF by activating the transcription of T cell–recruiting and –activating chemokines. (A–C) Triplicate bone
marrow–derived WT and Csf2ra−/− eosinophil cultures were treated overnight with 20 ng/ml recombinant GM-CSF or vehicle control and subjected to RNA-
sequencing–based transcriptome analyses. A heat map showing the top 500 differentially expressed genes that differed most across the 12 samples are shown
in A; the log2 ratio of expression of the indicated chemokine and cytokine genes in WT eosinophils treated with GM-CSF relative to control is presented in B;
the volcano plot in C shows all significantly differentially expressed transcripts (in red, significance cutoff P = 0.05, fold change >0.5), with the top transcripts
annotated with their gene names. (D and E) Expression of the indicated chemokine and cytokine transcripts in eosinophils FACS-sorted from adenomas versus
adjacent tissue (D; n = 6–8 samples per group) and MC38 tumors versus corresponding spleen (E; n = 8 samples per group). Each dot corresponds to sorted
eosinophils from one adenoma or MC38 tumor. ***, P < 0.001, as calculated by Mann–Whitney test.
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identified GM-CSF–IRF5 axis in eosinophils promotes MC38
tumor control.
Eosinophil infiltration of human CRC is associated with
superior survival and intratumoral CD8+ T cell infiltration
To examine the relevance of our findings for human CRC, we
generated a tissue microarray (TMA) comprising 240 well-
annotated cases of primary CRC treated in northwestern Swit-
zerland. We stained the array with H&E and EPO to quantify
eosinophil infiltration and with antibodies to CD3, CD8, lan-
gerin, and the mismatch repair proteins MLH1, MSH2, MSH6,
and PMS2 to assess for CD8+ T cell and dendritic cell infiltration
and microsatellite instability, respectively. Eosinophils were
readily detectable on H&E sections, and patients could be
stratified into eosinophilhigh (>3 eosinophils/0.785 mm2) and
eosinophillow (<3 eosinophils/0.785mm2) subsets (Fig. S5 A); the
cutoff score was generated by means of a ROC/AUROC function
to best meet prognostic significance (Tzankov et al., 2010). Of
223 evaluable primary tumors, 162 cases (73%) exhibited little
or no eosinophil infiltration, whereas 61 cases (27%) were clas-
sified as eosinophilhigh. Patients with eosinophilhigh tumors had a
significantly better progression-free survival (P = 0.046
Figure 7. GM-CSF-activated IRF5 is a critical regulator of eosinophil activities in the TME. (A–C) Splenocytes from IL-5–transgenic donors were treated
overnight with 20 ng/ml GM-CSF, 50 ng/ml IL-10, or both cytokines. Cells were either stained for phosphorylated IRF5 and the signal in eosinophils was
quantified by flow cytometry (A, summary plot of MFI and representative histogram, n = 4 technical replicates per condition) or subjected to protein extraction
and Western blotting with a p-IRF5-specific antibody (B, total IRF5 and GADPH shown as loading controls). The quantification of three Western blots rep-
resenting independent experiments is shown below the lanes as mean ± SEM. (C) The same cells as shown in A were also stained for Siglec F and CD11b to
assess the activation state of eosinophils in the cultures. (D) IRF5 activation as assessed by p-IRF5–specific flow cytometry of eosinophils in tumors of Eo-Cre ×
Il10ra fl/fl mice and their Cre-negative littermates. One representative experiment of two is shown, n = 4–5 tumors per genotype. (E) IRF5 activation as assessed
by p-IRF5–specific flow cytometry of eosinophils in tumors of Eo-Cre × Csf2rb fl/fl mice and their Cre-negative littermates that were treated three times weekly
with recombinant GM-CSF or PBS as indicated. (F) Tumor weights and volumes at the study endpoint of Eo-Cre × Irf5 fl/fl mice and their Cre-negative lit-
termates that had been subcutaneously injected with MC38 cells. Data are pooled from two independent experiments. (G) GM-CSF in CD45 negative leu-
kocytes (right panel, correlation coefficient ρ = −0.948) and p-IRF5 in eosinophils infiltrating adenomas of ApcMin/+ mice treated with isotype control antibody
(left panel, ρ = −0.927) as assessed flow cytometrically, relative to tumor counts (small intestine plus colon, as shown in Fig. 3). *, P < 0.05; **, P < 0.01; and ***,
P < 0.001; as calculated by Mann–Whitney test (D and F), by one-way ANOVA with Tukey’s post-test (A, C, and E) or by linear regression (G).
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according to the log rank Mantel–Cox test) than their eosino-
phillow counterparts (Fig. 8 A). The median progression-free
survival of patients with eosinophilhigh tumors was on average
15 mo longer (55 ± 2.17 mo) than that of patients with eosino-
phillow tumors (40 ± 3.35 mo). Furthermore, analysis of the
distribution of eosinophillow and eosinophilhigh tumors with
respect to pTNM staging revealed that eosinophil infiltration
was inversely correlated with pT stage, with higher proportions
of eosinophilhigh instances in stage 1 and 2 patients than in stage
3 and 4 patients (Fig. 8 B). Staining for CD8 revealed that, of 174
evaluable patients, 64 cases (37%) exhibited considerable infil-
tration by CD8+ tumor–infiltrating T cells (>30 cells/0.785mm2),
whereas 110 cases (63%) fell under that cutoff (see representa-
tive images in Fig. S5 B). As reported in other cohorts, high CD8+
T cell infiltration was associated with superior progression-free
survival (Fig. 8 C), and the difference of survival probability
between CD8+ T cellhi and CD8+ T celllo patients was highly
significant (P = 0.001 according to the log rankMantel–Cox test).
Eosinophilhigh tumors were further also infiltrated by larger
numbers of CD8+ T cells (Fig. S5 B); the positive association
between both parameters was highly significant (correlation
coefficient ρ = 0.411; P = 2.02 × 10−8). Indeed, the vast majority of
patients with eosinophilhigh tumors also exhibited high levels of
CD8+ T cell infiltration; the reverse was not true, as ∼25% of
CD8+ T cellhi tumors showed no or little eosinophil infiltration.
Other examined parameters (langerin-positive Langerhans cell
infiltration and microsatellite instability) had no detectable
impact on survival in our cohort (data not shown), although
langerin expression (and thus Langerhans cell infiltration), but
not microsatellite instability, correlated with eosinophil infil-
tration (correlation coefficient ρ = 0.305; P = 003). To address
whether eosinophils were differentially present in primary tu-
mors and metastases, we compared 36 matched primary and
metastasis pairs that had been arrayed on the TMA. The mean
number of eosinophils was considerably higher at the primary
sites (5.64/0.785 mm2 ± 13.47; range, 0–54) than at the meta-
static sites (mean 0.83/0.785 mm2 ± 2.80; range, 0–15; P = 0.049
according to the Wilcoxon paired/signed-rank test; Fig. 8 D),
suggesting that these distant sites are not efficiently targeted by
eosinophils. Eosinophils and T cells infiltrated the same areas of
the tumor if both cell populations were present, as shown for
two representative cases at low and high magnification (Fig. 8
E). In conclusion, the observations made in our Swiss cohort of
CRC patients confirms the previously noted superior survival of
patients harboring tumors with high densities of eosinophils or
CD8 T cells, establishes a close link between the two immune cell
populations in CRC, and indicates a considerably lower presence
of eosinophils at metastatic sites.
Discussion
Eosinophils constitute a versatile and highly heterogeneous cell
population with not only key functions in the settings of allergy
and parasitic infection but also antibacterial and regulatory
properties that are only beginning to be unraveled at the
mechanistic level. The work presented here adds yet another
previously understudied function to the eosinophil portfolio,
i.e., their contribution to antitumor immunity. Epidemiological
studies have long noted a superior prognosis of patients with
cancers of the gastrointestinal tract that exhibited high levels of
eosinophil infiltration, in terms of their rate of metastasis as
well as overall survival probability (Lotfi et al., 2007); our own
survey of 240 patients with CRC corroborated these early ob-
servations. In our cohort, eosinophil infiltration further corre-
lated positively with CD8+ T cell infiltration and inversely with
tumor stage, which supports our general hypothesis that eosi-
nophils promote tumor control through the activation of T cells.
Our experimental data suggest that eosinophils infiltrate sub-
cutaneously growing MC38 tumors and, along with monocytes
and NK cells, are among the first leukocyte populations to arrive
at the tumor site. The three strategies we have used to manip-
ulate eosinophil numbers demonstrate that eosinophils are
strictly required for tumor control. In the absence of eosinophils,
MC38 tumors are at least twice as large as their eosinophil-
replete counterparts. Our data also show that CT26 tumors
grow faster in BALB/c mice in the absence of eosinophils and
that eosinophil-depleted ApcMin/+ mice develop more tumors
in the small intestine and colon. The results obtained in
IL-5–transgenic mice further suggest that eosinophil infiltration
is a limiting factor in tumor control that can be overcome simply
by the excessive bonemarrow production of eosinophils under IL-
5 exposure. A detailed comparison of T cell tumor infiltrates in
eosinophil-replete versus depleted mice revealed lower frequen-
cies of activated CD4+ and CD8+ T cells expressing IFN-γ, TNF-α,
GM-CSF, and especially effector memory T cells, in PHIL mice
and mice subjected to anti–IL-5 treatment relative to their re-
spective controls; opposite effects were seen in tumors from IL-
5–transgenic mice. The dependence of tumor-specific T cell re-
sponses on eosinophils could not be attributed to a defect in T cell
priming; quite to the contrary, frequencies of activated (cytokine-
expressing) T cells in the draining inguinal LNs were higher in
PHIL mice than their WT counterparts. Rather, we attribute the
defect of PHIL and IL-5–depleted mice in tumor control to their
inability to drive the expansion of activated T cells at the tumor
site. The conclusions we draw from our observations regarding
the T cell dependence of the antitumor effects of eosinophils were
not shared by a recent study conducted in ApcMin/+ mice, which
also reported a critical role of eosinophils in controlling adenoma
formation in the ApcMin/+ model but linked the reduced tumor
burden of eosinophil-replete mice to direct cytotoxic activities of
eosinophils on tumor cells (Reichman et al., 2019).
GM-CSF is a potent cytokine promoting the differentiation of
myeloid cells, and both pro- and antitumor effects have been
reported (Hong, 2016). While GM-CSF can exert stimulatory
effects on tumor progression depending on the tumor type or
cancer model, it can also be used as an immunostimulatory ad-
juvant to elicit antitumor immunity. GM-CSF is already ad-
ministered in clinical trials, with clear benefit in certain cancer
settings, particularly when used in combination with checkpoint
inhibitors (Hodi et al., 2014). Both immune-dependent and in-
dependent mechanisms have been advanced to explain the
benefit of GM-CSF therapy (Yamashita et al., 1989; Mach et al.,
2000). Interestingly, GM-CSF is found to be overexpressed in
one third of CRCs, and patients whose tumors express both
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GM-CSF and the GM-CSF receptor have excellent 5-yr survival
rates (Urdinguio et al., 2013). In the TME, we have identified
GM-CSF and IL-10 as critical regulators of eosinophil activity
with opposing effects. Our data add to a growing body of evi-
dence implicating GM-CSF in many aspects of eosinophil biol-
ogy, including their development and survival at steady state
(Willebrand and Voehringer, 2016) and their activation (Griseri
et al., 2015) andmigration (Liu et al., 2015) during inflammation.
Studying GM-CSF is challenging due to the shared use of the
common β-chain of the GM-CSF receptor by IL-5 and IL-3; we
have been able to at least partly overcome this challenge through
the use of a mouse strain lacking the (specific) α-chain and of a
Cre recombinase that is expressed only after eosinophils have
exited the bone marrow. Indeed, eosinophil counts in the bone
marrow, blood and spleen are not significantly different in Eo-
Cre × Csf2rbfl/fl mice and their WT littermates but rather are
specifically reduced in the TME, along with the expression of
activation markers by the residual intratumoral eosinophil
population. Furthermore,we show that the beneficial effects of GM-
CSF administration on tumor control require the expression of the
GM-CSF receptor β-chain on eosinophils. The two observations
combined indicate that eosinophil activation at andmigration to the
tumor site both require GM-CSF signaling, with GM-CSF-activated
eosinophils driving CD4+ and CD8+ T cell responses.
Several observations implicate the transcription factor IRF-5
in signaling downstream of the GM-CSF receptor. On the one
hand, the specific loss of IRF5 in eosinophils phenocopies the
loss of the GM-CSF receptor β-chain with respect to tumor
control; on the other hand, the exposure of eosinophils in vitro
or in vivo to GM-CSF induces strong IRF5 phosphorylation. Our
data obtained with Eo-Cre × Il10rafl/fl mice suggest that the GM-
CSF–IRF5 axis is antagonized by IL-10; mice that lack IL-10R
expression in the eosinophil compartment control tumors more
efficiently than their WT littermates, and their eosinophil
Figure 8. Eosinophil densities in CRC have prognostic rel-
evance and are positively correlated with T cell infiltration.
(A) Progression-free survival of 61 patients whose tumors were
classified as eosinophilhigh (>3 eosinophils per 0.785 mm2)
versus 162 patients classified as eosinophillow (<3 eosinophils
per 0.785 mm2). P = 0.046 according to the log rank Mantel–
Cox test. (B) Stratification of eosinophilhigh and eosinophillow
patients according to their pTNM status. (C) Progression-free
survival of 64 cases whose tumors were classified as CD8high
(>30 CD8+ T cells per 0.785 mm2) versus 110 patients classified
as CD8low (<30 CD8+ T cells per 0.785 mm2). P = 0.001 ac-
cording to the log rank Mantel–Cox test. (D) Eosinophil infil-
tration into the primary tumor and metastases of 36 matched
pairs. P = 0.049 according to the Wilcoxon paired/signed-rank
test. (E) Representative low- and high-magnification images of
two stamp biopsy specimens included on our TMA that feature
high eosinophil (in green) and high CD3+ T cell infiltration (in
red), as assessed by immunofluorescence microscopy using
antibodies for CD3 and the eosinophil peroxidase. Scale bars
indicate 100 µm (left images) and 20 µm (right images),
respectively.
Arnold et al. Journal of Experimental Medicine 12 of 17
Eosinophils promote antitumor immunity https://doi.org/10.1084/jem.20190706
D
ow
nloaded from
 http://rupress.org/jem
/article-pdf/217/12/e20190706/1050166/jem
_20190706.pdf by U
niversitat Bern user on 28 Septem
ber 2020
“hyperactivation” in the absence of a regulatory IL-10 signal is
readily observed at the level of IRF5 phosphorylation. In vitro,
the IRF5 phosphorylation upon GM-CSF stimulation is reduced
by concomitant exposure to IL-10. We have begun to elucidate
the major sources of GM-CSF and IL-10 in the tumor context.
Myeloid cells (macrophages and monocytes) are the dominant
source of IL-10, with >80% of all IL-10–positive cells expressing the
myeloid cell markers CD11b, MHCII, and F4/80. Minor contributing
cell types are T cells, including regulatory T cells (T reg cells). In
contrast, GM-CSF is predominantly expressed by CD45-negative
stromal cells and T cells. Our data are consistent with eosinophils
serving as sensors and amplifiers of the environmental cues they
receive from theirmicroenvironment; in settingswith high levels of
GM-CSF produced by activated Th1-polarized T cells and stromal
cells, eosinophils promote further T cell activation and tumor con-
trol. Conversely, under conditions of high IL-10 production, eosi-
nophils dampen T cell responses and thereby compromise tumor
control. Our data are in line with a growing body of evidence at-
tributing both regulatory and proinflammatory properties to this
versatile cell type, with microenvironmental signals tipping the
balance in one or the other direction.
Targeting eosinophils through their systemic depletion by
antibodies specific for IL-5 or its receptor has recently received
much attention in a subset of difficult-to-treat asthma patients
with steroid-resistant disease, who often present with very se-
vere symptoms (Castro et al., 2011). The high specificity of IL-5
for eosinophils, the critical role of IL-5 in eosinophil biology and
its involvement in the majority of eosinophilic conditions make
it a very attractive target for the treatment of eosinophil-
mediated disorders other than asthma, with clinical trials
currently ongoing in patients with eosinophilic esophagitis, id-
iopathic hypereosinophilic syndrome, and chronic rhinosinusi-
tis with nasal polyposis (Roufosse, 2018). The widespread use of
IL-5–targeting therapies in patients with asthma, and potentially
soon in patients with other eosinophil-driven conditions, means
that large numbers of individuals will essentially be living
without eosinophils in the very near future. The consequences
of prolonged eosinophil depletion are only beginning to be de-
bated, mostly with respect to susceptibility to parasitic infection
(Gleich et al., 2013). Our recent work on the role of eosinophils in
the maintenance of gastrointestinal homeostasis and bacterial
infection control (Arnold et al., 2018), as well as the current study
investigating eosinophil functions in the context of tumor im-
munity, suggests that patient populations under IL-5 treatment
need to be closely monitored in phase 4 trials for possibly en-
hanced susceptibility to bacterial infections of the gastrointestinal
tract as well as (gastrointestinal tract) malignancies. A better
understanding of eosinophils functions in both health and disease,
gained through the use of experimental models of eosinophil de-
ficiency, will contribute to informed treatment choices that weigh
both the benefits and risks of prolonged eosinophil depletion.
Materials and methods
Patient cohort and TMA construction
Our cohort consisted of a total of 240 fully and irreversibly
anonymized patients with therapy-naive, surgically resected
CRC, of whom 98 were female (41%) and 142 were male (59%).
The median follow-up of the cohort was 33 mo, with a range
of 0–235 mo. Cores of primary tumors and, in 36 instances,
(matched) corresponding metastases, were brought into a TMA.
At the time of last follow up update, 97 patients were alive (41%),
30 were dead with/on disease (13%), 61 (25%) had died of un-
known causes, and 52 had developed metachronous metastases.
The pathological tumor-node-metastasis (pTNM) distribution at
the time of diagnosis of our cohort was as follows: pT1, 11 pa-
tients (5%); pT2, 35 patients (17%); pT3, 118 patients (57%); pT4,
43 patients (21%); the pT stage of 33 cases could not be deter-
mined; pN0, 96 patients (47%); pN1, 77 patients (38%); pN2, 30
patients (15%); pN3, 1 patients (0.5%); the pN stage of 36 cases
could not be determined; pM0, 98 patients (53%); pM1, 87 pa-
tients (47%); the pM stage of 55 cases was unknown. The pTNM
staging was done according to the sixth edition of the AJCC
Cancer Staging Manual (American Joint Committee on Cancer,
2002). Eosinophils were identified on H&E-stained slides based
on their specific morphological appearance with large eosino-
philic metachromatic granules. Immunohistochemical stainings
for CD8, langerin, MLH1, MSH2, MSH6, and PMS2 were per-
formed on an automatic platform (Benchmark Ultra; Roche/
Ventana) using the following primary antibodies: CD8 (clone
SP57, 790–4460 RTU-kit; Roche/Ventana), langerin (clone 12D6,
NCL-langerin at a dilution of 1:100; Novocastra), MLH1 (clone
M1, 790–4535 RTU-kit; Roche/Ventana), MSH2 (clone Q219-1129,
760–4265 RTU-kit; Roche/Ventana), MSH6 (clone EP49,
IR08661 RTU-kit; DAKO/Agilent), and PMS2 (clone EP51 by
IR08761 TRU-kit; DAKO/Agilent). Ethical approval for the TMA
construction and research based on that TMAwas obtained from
the Ethics Committee of Northwestern Switzerland #361/12
formApril 11, 2012. According to Swiss law, no informed consent
is needed for retrospective archival tissue-based studies of fully
and irreversibly anonymized patients, provided the tissue has
been obtained before 2012, the tissue is not exhausted, and the
patients have not put a veto on research with their tissues; all of
these conditions applied to the cases on the TMA.
Animal experimentation
C57BL/6J (stock no. 000664), B6(SJL)-Il10ratm1.1Tlg/J (stock no.
028146), B6;129-Tgfbr2tm1Karl/J (stock no. 012603), C57BL/6-
Irf5tm1Ppr/J (stock no. 017311), and C57BL/6J-ApcMin/J (stock no.
002020) mice were obtained from The Jackson Laboratory. IL-
5–transgenic (Dent et al., 1990) and Csf2rbfl/fl (Croxford et al.,
2015) mice have been described previously. Eosinophil-deficient
mice (PHIL; Lee et al., 2004) and mice expressing Cre under the
Eo-Cre (Doyle et al., 2013) were obtained from J.J. Lee (Mayo
Clinic, Phoenix, AZ). IL-10 reporter (10BiT) mice (Maynard et al.,
2007) and Csf2ra−/− mice (Schneider et al., 2017) were described
previously. All strains were bred and maintained under specific
pathogen–free conditions in accredited animal facilities at the
University of Zurich. For the depletion of eosinophils, WT or
ApcMin mice were i.p. injected two times per week with 0.25 mg
anti–IL-5 antibody (TRFK5; BioXCell) or anti-horseradish per-
oxidase isotype control antibody (HRPN; BioXCell) starting from
2 d before MC38 inoculation (WT) and at 12 wk of age (ApcMin).
PD-L1–blocking antibody (10F.9G2; BioXCell), CTLA4-blocking
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antibody (9H10; BioXCell), CD8-depleting antibody (YTS 169.4;
BioXCell), and TNF-α–neutralizing antibody (XT3.11; BioXCell)
were i.p. administered two times per week at doses of 0.5 mg/
mouse. 100 ng recombinant GM-CSF or IL-5 (PeproTech) was i.p.
administered three times per week. All animal experimentation
was reviewed and approved by the Zurich Cantonal Veterinary
Office (licenses ZH224/2014, ZH140/2017, and ZH021/2020 to A.
Müller).
Syngeneic tumor models and genome editing by CRISPR
The murine CRC cell line MC38 is derived from C57BL/6 mice
and the CT26 line is derived from BALB/c mice; both were
generously provided by Prof. Lubor Borsig (University of Zurich,
Zurich, Switzerland). Cells were maintained in DMEM supple-
mented with 100 U/ml penicillin/streptomycin and 10% heat-
inactivated FCS at 37°C in 5% CO2. 5 × 105 MC38 cells were
subcutaneously injected in both flanks of mice, and the tumors
were analyzed after 15 d for tumor weight, volume, leukocyte
infiltration, and RNA expression profile. For the generation of
MC38 cells lacking TNFRI, the guide RNA for TNFRSF1A (59-GTG
TCTCACTCAGGTAGCGT-39) was cloned into PX458 vector
(#48138: pSpCas9 (BB)-2A-GFP; Addgene). 3 × 105 MC-38 cells
were transfected with 2.5 µg plasmid using TransIT2020
transfection reagent (Mirus Bio). GFP-positive cells were FACS
sorted 48 h after transfection. After four passages, MC-38 cells
were bulk sorted based on their TNFRI expression and enriched
for a TNFRIlow population and a WT population.
Leukocyte isolation and flow cytometry
For leukocyte isolation of MC-38 tumors, 80–100-mg tumor
slices were cut into pieces and digested in 500 U/ml type IV
collagenase and 0.05 mg/ml DNase I at 37°C for 50 min under
agitation in supplemented RPMI-1640 medium, followed by
pushing through a cell strainer. For leukocyte isolation of
ApcMin/+ tumors or of adjacent normal colonic lamina propria,
tissues were weighted, cut into pieces and incubated in HBSS
with 10% FCS and 5 mM EDTA at 37°C in a shaking incubator.
Tissues were then digested at 37°C for 50 min with 15 mM
Hepes, 500 U/ml type IV collagenase (Sigma-Aldrich), and
0.05 mg/ml DNase I in RPMI-1640 medium supplemented with
10% FBS and 100 U/ml penicillin/streptomycin. LN cell sus-
pensions were prepared by digesting the LNs in 500 U/ml type
IV collagenase in RPMI-1640 for 15 min followed by pushing
through a cell strainer using a syringe plunger. Splenocytes
were prepared by mashing the spleens through a cell strainer
using a syringe plunger, followed by red blood cell lysis with
ACK buffer. Blood was removed by terminal cardiac puncture
and subjected to ACK red blood cell lysis. Bone marrow cells
were collected by flushing the mouse femur and the tibia with
RPMI medium. Total leukocyte counts were determined by
adding countBright Absolute Counting Beads (Life Technologies)
to each sample before flow cytometry for normalization to tissue
weight. Cells were stained with a fixable viability dye and a
combination of the following antibodies: anti-mouse CD45
(clone 30-F11), CD11c (N418), MHCII (M5/114.15.2), F4/80 (BM8),
CD11b (M1/70), Ly6G (1A8), Ly6C (HK1.4), CD4 (RM4-5), CD8
(53–6.7), NK1.1 (PK136), TCR-β (H57-597), CD44 (1M7), CD62L
(MEL-14), CD69 (H1.2F3), Thy1.1 (OX-7), CD63 (NVG-2), and
CCR3 (J073E5; all from BioLegend), as well as Siglec F (E50-2440;
BD Biosciences) and β-integrin (TS2/16; eBioscience), CD120a
(TNFR type I/p55; clone 55R-286), and Armenian hamster
IgG isotype control (clone HTK888). Fc block (anti-CD16/CD32;
Affymetrix) was included to minimize nonspecific antibody
binding. Annexin V staining was performed with the Annexin
V Apoptosis Detection Set (eBioscience) according to the man-
ufacturer’s instructions. For intracellular cytokine staining of
T cells, cells were incubated at 37°C for 3.5 h in complete IMDM
containing 0.1 µM PMA and 1 µM ionomycin with 1:1,000
brefeldin A (eBioscience) and GolgiStop solutions (BD Bio-
sciences) at 37°C in a humidified incubator with 5% CO2. To
assess tumor-specific T cell responses, MC38 tumor cell sus-
pensions were restimulated with the H-2Kb–restricted MC38
peptide KSPWFTTL at 37°C for 3.5 h in complete IMDM con-
taining brefeldin A and GolgiStop solutions. For the detection of
intracellular cytokine production by myeloid and tumor cells,
cell suspensions were incubated at 37°C for 3 h in complete
IMDM containing only brefeldin A. Following surface staining,
cells were fixed and permeabilized with the Cytofix/Cytoperm
Fixation/Permeabilization Solution Kit (BD Biosciences) ac-
cording to the manufacturer’s instructions. Cells were then
stained for 50 min with antibodies to IFN-γ (XMG1.2), TNF-α
(MP6-XT22), GM-CSF (MP1-22E9), IL-10 (JES5-16E3), or CCL5
(2E9). For the intracellular staining of granzyme B (QA16A02;
BioLegend), p-IRF5 (p-Ser437, polyclonal; Thermo Fisher Sci-
entific), IRF5 (polyclonal; Abcam), or Ki-67 (11F6; BioLegend), cells
were surface stained followed by fixation and permeabilization
with the Foxp3/Transcription Factor Staining Buffer Set (eBio-
science) according to manufacturer’s instructions. Samples were
acquired on a LSRII Fortessa (BD Biosciences) and analyzed using
FlowJo software.
For quantitative PCR, RNA was isolated using the RNeasy
Mini Kit (Qiagen) according to the manufacturer’s instructions,
and complementary DNA synthesis was performed using Su-
perscript III reverse transcription (Qiagen). Quantitative PCR
reactions for the following candidate genes were performed
using TaqMan gene expression assays (Applied Biosystems
by Thermo Fisher Scientific): Ccl2 (Mm00441242_m1), Ccl4
(Mm00443111_m1), Ccl17 (Mm00516136_m1), Ccl22 (Mm00436
439_m1), Ccl24 (Mm00444701_m1), Csf2 (Mm01290062_m1),
Hprt (Mm03024075_m1), Irf5 (Mm00496477_m1), and Tnfa
(Mm00443258_m1). Complementary DNA samples were ana-
lyzed using a Light Cycler 480 detection system (Roche) and
gene expression levels for each sample were normalized to
HPRT expression. Mean relative gene expression was deter-
mined, and the differences were calculated using the 2ΔC(t)
method.
Differentiation of bone marrow–derived eosinophils, in vitro
stimulation experiments, and immunoblotting
To generate murine bone marrow–derived eosinophils, bone
marrow stem cells from donor mice were flushed from the fe-
mur and the tibia and resuspended in RPMI-1640 medium upon
red blood cell lysis. Cells were seeded at a density of 106 cells/ml
in RPMI-1640 medium supplemented with 20% heat-inactivated
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FBS, 25 mM Hepes, 100 U/ml penicillin/streptomycin, 2 mM
glutamine, 1× NEAA, and 1mM sodium pyruvate, and cultured at
37°C. BM Eos were differentiated with 100 ng/ml mouse stem
cell factor (PeproTech) and 100 ng/mlmouse FLT3L (PeproTech)
from days 0 to 4, followed by differentiation with 10 ng/ml
mouse IL-5 (PeproTech) only from day 4 onwards, as described
previously (Dyer et al., 2008). At day 12, eosinophils were re-
suspended in DMEM supplemented with 10 ng/ml recombinant
IL-5 (PeproTech), 100 U/ml penicillin/streptomycin, and 10%
heat-inactivated FCS and co-cultured with MC38 cells upon
stimulation with cytokines (TSLP, IFN-γ, TNF-α, GM-CSF,
20 ng/ml; PeproTech). Cells were stained with Annexin V (Bi-
oLegend) according to the manufacturer’s instructions and an-
alyzed by flow cytometry. To analyze IRF5 and p-IRF5
expression in vitro, total splenocytes or eosinophils purified
from the spleens of IL-5 transgenic mice by MACS (positive
selection using anti-Siglec F-PE with anti-PE microbeads) were
cultured overnight in RPMI-1640 medium supplemented with
20% heat-inactivated FBS, and 100 U/ml penicillin/strepto-
mycin in the presence of recombinant IL-5 (10 ng/ml) and
stimulated with recombinant GM-CSF and/or IL-10 (all from
PeproTech) at the indicated concentrations. Cells were either
stained for IRF5 and phosphorylated IRF5 and the signal in
eosinophils was quantified by flow cytometry or were sub-
jected to protein extraction and immunoblotting. Proteins were
extracted in RIPA buffer (Sigma-Aldrich) supplemented with 1×
complete protease inhibitor cocktail (Roche), 0.5 mM sodium
orthovanadate, 1 mM benzamidine, and PMSF. Protein con-
centration was quantified by the Bradford method (Bio-Rad),
and samples were denatured in SDS, separated by SDS-PAGE
(10% gel), transferred to polyvinylidene fluoride membranes,
and immunoblotted with antibodies specific for IRF5, p-IRF5,
and GAPDH.
RNA sequencing and data analysis
For the RNA sequencing, live bone marrow–derived eosinophil
cultures from WT and Csf2ra−/− mice were purified using the
Dead Cell Removal Kit (Miltenyi Biotech), seeded at a density of
106 cells/well in RPMI-1640 medium supplemented with 10%
heat-inactivated FBS, 100 U/ml penicillin/streptomycin, and
recombinant IL-5 (10 ng/ml). Cell triplicates were stimulated
overnight with 20 ng/ml recombinant GM-CSF at 37°C or left
untreated. RNA was isolated using the RNeasy Mini Kit (Qia-
gen), including an on-column DNA digestion step. Total RNA
was submitted to the Functional Genomics Center Zurich.
Samples were analyzed for RNA integrity and concentration
using the RNA Screen Tape (Agilent were suitable for a Tru-
Seq stranded mRNA library preparation; Illumina). After
poly(A) selection using Oligo-dT beads, mRNA was reverse
transcribed into cDNA. The cDNAwas fragmented, end repaired,
and polyadenylated before ligation of TruSeq UD Indices (IDT).
The quality and quantity of the amplified sequencing libraries
were validated using a Fragment Analyzer SS NGS Fragment Kit
(1–6,000 bp; Agilent). The equimolar pool of samples was spiked
into a NovaSeq6000 run targeting 600 million reads on a S2
FlowCell (Novaseq S2 Reagent Kit, 100 cycles; Illumina). The Bcl
files were demultiplexed using bcltofastq software (Illumina).
RNA-sequencing reads were aligned with the STAR aligner. As
reference we used the Ensembl mouse genome build GRCm38.p6
using the gene annotation as provided by GENCODEM23 release.
Gene expression values were computed with the function fea-
tureCounts from the R package Rsubread. Differential expression
was computed using the Bioconductor package EdgeR. In par-
ticular, the glmQLFit functionwas used to fit the quasi-likelihood
negative binomial generalized log-linear model to the count data
and running quasi-likelihood F-test.
Confocal immunofluorescence microscopy
Paraffin-embedded mouse tissue section or human TMA slides
were deparaffinized and rehydrated with graded ethanol dilu-
tions. After antigen retrieval in a pressure cooker using EDTA-Tris
buffer (10 mM Tris base and 1 mM EDTA, pH 9.0), nonspecific
binding was prevented by preincubation of tissue sections with a
blocking buffer (PBS containing human immunoglobulins, normal
goat serum, and 7.5% BSA) at room temperature for 1 h. Indirect
immunofluorescence staining was performed by incubating
the paraffin sections with mouse monoclonal anti-EPX anti-
body (1:200; clone MM25-82 2; obtained from Lee Laboratories,
Mayo Clinic) and rabbit monoclonal anti-CD3 antibody (1:20;
clone SP7; Thermo Fisher Scientific, distributed by LuBio-
Science), in blocking solution, at 4°C, overnight. After several
washes in PBS, secondary Alexa Fluor 488–conjugated goat
anti-mouse (1:400) and Alexa Fluor 532–conjugated goat anti-
rabbit (1:400) antibodies (Thermo Fisher Scientific) were ap-
plied and tissue samples incubated at room temperature for 1 h.
Samples were washed and mounted in Prolong Gold mounting
medium (Thermo Fisher Scientific), and image acquisition was
performed using confocal laser scanning microscopy LSM 700
(Carl Zeiss Micro Imaging) with a 20× or 40×/1.40 oil DIC ob-
jective and analyzed with IMARIS software (Bitplane AG).
Statistical analysis
Statistical analysis was performed with Prism 6.0 (GraphPad
Software) and with SPSS 22.0. The nonparametric Mann–
Whitney U, Spearman rank correlation, and the log rank
Mantel–Cox tests in combination with Kaplan–Meier curves and
one-way ANOVA with Tukey’s post-test were used, where ap-
propriate, for statistical analyses. Differences were considered
statistically significant when P < 0.05 (*, P < 0.05; **, P < 0.01;
***, P < 0.001).
Online supplemental material
Fig. S1 shows the gating strategy and absolute numbers of
the tumor-infiltrating leukocyte populations as well as eosino-
phil frequencies of WT, PHIL, anti–IL-5 antibody–treated and
IL-5–transgenic mice. Fig. S2 shows CD4+ and CD8+ T-cell re-
sponses in tumors and tumor-draining lymph nodes upon ma-
nipulation of the eosinophil compartment. Fig. S3 shows the
effect of manipulating the IL-10/STAT3 signaling axis on sub-
cutaneous MC38 tumor growth and T cell responses. Fig. S4
shows eosinophil and myeloid cell frequencies in the tumors
and tissues of Eo-Cre × Csf2rbfl/fl and CSF2ra−/− mice. Fig. S5
shows representative H&E- and anti-CD8–stained sections of
CRC biopsy specimens.
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Figure S1. Eosinophil depletion and overproduction by IL-5 neutralization or transgenic expression. (A) Gating strategy to identify eosinophils and CD4+
and CD8+ T cells among tumor-infiltrating CD45+ leukocytes. (B) Absolute numbers of the indicated tumor-infiltrating leukocyte populations, as quantified per
mg of tumor tissue, of the tumors shown in Fig. 1 B. (C and D) Intratumoral eosinophil frequencies of WT, PHIL, anti–IL-5 antibody–treated and IL-5–transgenic
mice; representative plots are shown in C along with summary plots in D of all the mice shown in the main Fig. 1. (E) Expression of the indicated surface
markers on intratumoral eosinophils from IL-5–transgenic mice and their WT littermates. Data are from one representative study (n = 6–7 mice per genotype).
*, P < 0.05; **, P < 0.01; ***, P < 0.001; as calculated by Mann–Whitney test (D and E) or by one-way ANOVA with Tukey’s post-test (B).
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Figure S2. The manipulation of the eosinophil compartment modulates T cell responses in the tumor and draining LNs. (A) Tumor weights and
volumes at the study endpoint of WT mice injected with MC38 cells and treated twice weekly with 250 µg/dose of a CD8+ T cell–depleting antibody or its
isotype control (n = 9–10 tumors per group). (B) CD4+ and CD8+ T cell frequencies among all leukocytes (upper panels) and absolute numbers per milligram of
tumor tissue (lower panels) of PHIL, anti–IL-5 antibody–treated, and IL-5–transgenic mice shown in main Fig. 2 relative to their WT littermates. (C) Intra-
tumoral frequencies of IFN-γ+ and TNF-α+ CD4+ and CD8+ T cells as assessed by intracellular cytokine staining upon restimulation with PMA/ionomycin and of
CD8+ T cells upon restimulation with MC-38–specific peptide of the anti–IL-5–treated mice shown in Fig. 1 G. (D) Frequencies of CD4+ and CD8+ T cells among
all leukocytes in the tumor-draining inguinal LNs of MC38 tumor-bearing relative to naive mice (left panels, n = 10–13 LNs per group) and of tumor-bearing
PHIL, IL-5–transgenic, and anti–IL-5–treated mice and their WT littermates presented in main Figs. 1 and 2 (right panels). (E) Frequencies of IFN-γ+ and TNF-α+
CD4+ and CD8+ T cells as assessed by intracellular staining upon restimulation with PMA/ionomycin, in the inguinal LNs of tumor-bearing PHIL, IL-
5–transgenic, and anti–IL-5–treated mice and their WT littermates (n = 5–21 LNs per group). (F–I) ApcMin/+ mice were treated twice weekly with 250 µg
of anti–IL-5 or isotype control antibody for 3 wk beginning at 12 wk of age. At the study endpoint, small intestinal and colonic adenomas were harvested along
with adjacent normal (tumor-free) colonic tissue per mouse for flow cytometric analysis. Small intestinal adenoma counts are shown in F (n = 14–17 mice per
condition); frequencies of Ki67+ cells among all CD4+ T cells and CD8+ T cell counts are shown for colonic adenomas and adjacent colonic lamina propria in G
and H. Frequencies of IFN-γ+ cells among all CD8+ T cells of tumor and adjacent normal tissue are shown in I. Data in D and G are from one representative study
in E and H and from two pooled studies and in F and I from three pooled studies. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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Figure S3. The IL-10–STAT3 signaling axis in eosinophils suppresses their antitumor properties. (A) Frequencies of Thy1.1 (IL-10)+ cells in the indicated
cellular compartments of the colonic lamina propria in (naive) IL-10 reporter (10BiT) mice (n = 8 mice). Means + SD are shown. (B) Representative FACS plot of
Thy1.1 (IL-10) expression by intratumoral Foxp3+ T reg cells and IL-10 expression by MC38 tumor cells growing subcutaneously in mice as determined by
intracellular cytokine staining relative to FMO (fluorescence minus one control). FSC-A, forward scatter area; L/D, live/dead. (C) WT C57BL/6 mice were
subcutaneously injected with 5 × 105 MC38 cells, treated twice weekly with anti–IL-10R or control antibody for the duration of the experiment, and analyzed
after 15 d with respect to their tumor weights and volumes (n = 10 tumors per group). (D) Ccl5 expression by intratumoral eosinophils in Eo-Cre × Il10rafl/fl mice
relative to their WT littermates (n = 17–20 tumors per genotype). (E–G) Eo-Cre × Stat3fl/fl mice and their WT littermates were subcutaneously injected with 5 ×
105 MC38 cells and analyzed after 15 d with respect to their tumor weights and volumes (E) and their intratumoral frequencies of IFN-γ+ and TNF-α+ CD4+ and
CD8+ T cells as assessed by intracellular cytokine staining upon restimulation with PMA/ionomycin (n = 9–10 tumors per genotype). (H) Eo-Cre × Tgfbr2fl/fl mice
and their Cre-negative littermates were subcutaneously injected with 5 × 105 MC38 cells and analyzed after 15 d with respect to their tumor weights and
volumes (n = 7–12 tumors per genotype). Data in C and H are from one experiment, data in D are pooled from three independent experiments, and data in E–G
are pooled from two independent experiments. (I) Apoptosis rate as determined by Annexin V staining followed by flow cytometry of MC38 cells cultured
overnight in the presence or absence of 10 ng/ml of the indicated recombinant cytokines and in the presence or absence of bone marrow–derived eosinophils
at a ratio of 2:1 (tumor/eosinophil). (J) TNFRI expression of MC38 cells subjected to genomic editing with a TNFRI-specific guide RNA (in blue) or an irrelevant
guide RNA (gray); cells were stained with a TNFRI-specific (gray, blue) or control antibody (black). (K and L) Apoptosis as determined by Annexin V staining
followed by flow cytometry, of MC38 cells described in J cultured o/n in the presence or absence of the indicated concentrations of TNF-α. A representative
Annexin V histogram is shown in K and a summary plot of four replicate samples per condition from two independent experiments is shown in L. (M) Tumor
weights and volumes at the study endpoint of Eo-Cre × Il10ra fl/fl mice and their Cre-negative littermates injected with MC38 cells, and treated twice weekly
with 250 µg/dose of a TNF-α–neutralizing antibody or its isotype control (n = 4–10 tumors). (N) Tumor weights and volumes at the study endpoint of Eo-Cre ×
Il10ra fl/fl mice that have been subcutaneously injected with MC38 cells that express either normal (TNFRI+) or low amounts (TNFRI−) as shown in J due to
CRISPR-mediated deletion of the TNFR1 locus (n = 12–16 tumors per group). The tumor size on day 10 is shown alongside tumor sizes and weights at the study
endpoint (day 15). *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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Figure S4. GM-CSF promotes tumor control through the activation of IRF5, but does not synergize with checkpoint blockade. (A) Systemic eosinophil
frequencies are not affected by the deletion of Csf2rb in the eosinophil compartment. Eo-Cre × Csf2rbfl/fl mice and their Cre-negative littermates were examined
with respect to their eosinophil frequencies, as determined by flow cytometry of the indicated tissues (n = 3–4 mice per genotype). (B) Eosinophil frequencies
in the tumors of Eo-Cre × Csf2rbfl/fl mice and their Cre-negative littermates (n = 10–11 tumors per genotype). (C) Myeloid cell frequencies in the tumors of
CSF2ra−/− mice and WT (n = 13–17 tumors per genotype). Data are pooled from two studies. (D) ApcMin/+ mice were treated three times weekly with re-
combinant GM-CSF during the last 3 wk of a 4-mo experiment. At the study endpoint, adenoma formation in the colon was quantified by counting individual
polyps with diameters of >1 mm. Data are from one experiment and representative of two (n = 5–8 mice per group). (E) WT BALB/c mice were injected with
CT26 cells and treated three times weekly with recombinant GM-CSF and/or twice weekly with a PD-L1–specific or isotype control antibody as indicated.
Tumor weights and volumes are plotted for one large study (n = 10–15 tumors per group). (F) WT C57BL/6 mice were injected with MC38 cells and treated
three times weekly with recombinant GM-CSF and/or twice weekly with a PD-L1–specific or CTLA4-specific antibody or isotype control as indicated. Tumor
weights and volumes are pooled from two independently conducted studies (n = 6–13 tumors per group). (G) Expression of the indicated immune
response–related transcripts in bone marrow–derived WT eosinophil cultures that were treated overnight with 20 ng/ml recombinant GM-CSF or vehicle
control and subjected to RNA-sequencing–based transcriptome analyses, as shown in Fig. 6. The log2 ratio is shown for GM-CSF–treated cells relative to
control. (H) GM-CSF (Csf2) expression, as determined by quantitative RT-PCR, in adenomas harvested from ApcMin/+ mice relative to adjacent control tissue.
Each data point represents one tumor or tissue, respectively (n = 20 samples per condition). (I) GM-CSF expression, as determined by FACS, of subcutaneously
growing MC38 cells at the study endpoint relative to FMO (fluorescence minus one control). (J) Splenocytes from IL-5 transgenic donors were treated for
30 min with the indicated amount of recombinant GM-CSF, or with 100 ng/ml LPS and stained for lineage markers and for phosphorylated IRF5; the p-IRF5
signal in Siglec F-positive eosinophils (left panel) and F4/80-positive macrophages (right panel) was quantified by flow cytometry. (K) Splenocytes from IL-
5–transgenic donors were treated overnight with 20 ng/ml GM-CSF. Cells were stained for IRF5 and the signal in eosinophils was quantified by flow cytometry.
The summary plots in J and K show the MFI (n = 4–5 parallel cultures each). (L) IRF5 expression, as determined by quantitative RT-PCR in sorted eosinophils
from IL-5–transgenic splenocyte cultures that have been exposed overnight to 20 ng/ml GM-CSF (n = 3–4 samples per condition). (M) Eosinophil activation in
tumors of Eo-Cre × Irf5fl/fl mice and their WT littermates, as assessed by flow cytometric analysis of Siglec F expression (n = 5–6 per genotype, P = 0.053.
(N) Tumor weights and volumes of Eo-Cre × Irf5fl/fl mice and their WT littermates that have (black circles) or have not (white circles) been treated with
recombinant GM-CSF three times weekly for the duration of the 2-wk experiment (n = 5–13 tumors per group). Data are pooled from two studies. *, P < 0.05;
**, P < 0.01; ***, P < 0.001.
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Figure S5. Eosinophils colocalize with CD8+ T cells in human CRC biopsy specimens. (A and B) Representative consecutive H&E-stained (A) and anti-
CD8–stained (B) sections of CRC biopsy specimens showing either low (upper panels) or high (lower panels) eosinophil infiltration into the tumor mass. Scale
bars indicate 100 µm.
Arnold et al. Journal of Experimental Medicine S6
Eosinophils promote antitumor immunity https://doi.org/10.1084/jem.20190706
D
ow
nloaded from
 http://rupress.org/jem
/article-pdf/217/12/e20190706/1050166/jem
_20190706.pdf by U
niversitat Bern user on 28 Septem
ber 2020
